GlassScriptPhysician profile
Brian A Lynch
NPI 1629492350
$248.63
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $192 · 2022: $56.46.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $99.99 | 2021 | |
| Novo Nordisk INC | $53.55 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.45 | 2022 | |
| Medtronic, INC. | $14.37 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.75 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.40 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.24 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.44 | 2022 | |
| Lilly USA, LLC | $11.44 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.